Targeting HER2, BRAF, KRAS, MET, TRK
Potential and progress in targeting less common markers: HER2, BRAF, KRAS, MET, TRK, and RETПодробнее
Debate: Are novel targets such as HER2 ready for prime time in colorectal cancer? - NoПодробнее
Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhDПодробнее
BRAF Mutations in Colorectal CancerПодробнее
KRAS, BRAF and RAS Webinar | Fight Colorectal CancerПодробнее
Targeting HER2, BRAF, KRAS, METПодробнее
Extreme Rare Mutations in Lung Cancer (ROS1, TRK, HER2): Treatment opportunitiesПодробнее
HER-2/BRAF/KRAS and METПодробнее
Targeting HER2 in Colorectal CancerПодробнее
AC21 - Ardaman Shergill: MAPK Pathway Targeting in CholangiocarcinomaПодробнее
Panel Discussion Targeting KRASПодробнее
Case 3: KRAS-Mutated Metastatic Colon CancerПодробнее
GRACE Targeted Therapies Lung Cancer 2021 - New Therapies: NTRK, RET and HER2Подробнее
Frontline Treatment for KRAS Wild-Type mCRCПодробнее
Dr. Desai on BGB-283 in Patients With BRAF or KRAS/NRAS Solid TumorsПодробнее
HER2 Targeted Therapy for Treatment of NSCLCПодробнее
Novel therapies beyond immunotherapy for GI MalignanciesПодробнее